Compare OEC & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | PYXS |
|---|---|---|
| Founded | 1862 | 2018 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.3M | 243.5M |
| IPO Year | 2014 | 2021 |
| Metric | OEC | PYXS |
|---|---|---|
| Price | $5.23 | $1.16 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $7.00 | $6.75 |
| AVG Volume (30 Days) | 521.4K | ★ 1.8M |
| Earning Date | 02-18-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,829,200,000.00 | $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.35 | $0.83 |
| 52 Week High | $16.63 | $5.55 |
| Indicator | OEC | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 22.91 |
| Support Level | $5.06 | $1.03 |
| Resistance Level | $5.39 | $4.58 |
| Average True Range (ATR) | 0.17 | 0.28 |
| MACD | 0.03 | -0.21 |
| Stochastic Oscillator | 51.19 | 3.52 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing and special applications. Geographically, it derives a majority of its revenue from Germany.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.